| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/19/2006 | EP1680093A1 Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and l-arginine alpha-ketoglutarate |
| 07/19/2006 | EP1680092A2 Pharmaceutical formulation with improved stability |
| 07/19/2006 | EP1680091A1 A solid dosage form comprising a fibrate |
| 07/19/2006 | EP1680090A2 Process for production of essentially solvent-free small particles |
| 07/19/2006 | EP1680089A1 Composition comprising biodegradable hydrating ceramics for controlled drug delivery |
| 07/19/2006 | EP1680086A2 A solid dosage form comprising a fibrate and a statin |
| 07/19/2006 | EP1680084A2 A multiple route medication for the treatment of rhinitis and asthma |
| 07/19/2006 | EP1680083A1 Compositions and dosage forms for ehnanced absorption of iron |
| 07/19/2006 | EP1680082A1 Compositions and dosage forms for enhanced absorption of metformin |
| 07/19/2006 | EP1680080A2 Neutrophil activation by immune response modifier compounds |
| 07/19/2006 | EP1680079A2 Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents |
| 07/19/2006 | EP1680066A2 Personal care composition containing a detersive surfactant, an antidandruff component, and ketoamide surfactants |
| 07/19/2006 | EP1680009A2 Compositions and methods for diagnosing and treating mental disorders |
| 07/19/2006 | EP1679991A2 Folding table and bench system |
| 07/19/2006 | EP1679980A1 Synergism of gos and polyfructose |
| 07/19/2006 | EP1679967A2 Methods of using and compositions comprising selective cytokine inhibitory drus for treatment, modification and management of pain |
| 07/19/2006 | EP1679966A2 Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides |
| 07/19/2006 | EP1679965A2 Substituted fused heterocyclic c-glycosides |
| 07/19/2006 | EP1679964A2 Compostions and processes using sirna amphipathic compounds and polycations |
| 07/19/2006 | EP1638492A4 Preoperative treatment of post operative pain |
| 07/19/2006 | EP1532124B1 Use of nitrile derivatives as medicament. |
| 07/19/2006 | EP1506194B1 SUBSTITUTED RING-FUSED IMIDAZOLE DERIVATES: GABA sb A /sb RECEPTOR LIGANDS |
| 07/19/2006 | EP1492769B1 Novel process for the preparation of 1-phenyl-2-(2-pyridyl)ethanamine |
| 07/19/2006 | EP1476166B1 Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases |
| 07/19/2006 | EP1444215B1 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| 07/19/2006 | EP1399142B1 Use of acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus |
| 07/19/2006 | EP1395575B1 4-(penyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |
| 07/19/2006 | EP1395273B1 Targeted delivery of drugs for the treatment of viral infections |
| 07/19/2006 | EP1393277B1 USE OF NF-Kappa-B INHIBITORS TO TREAT DRY EYE DISORDERS |
| 07/19/2006 | EP1379695B1 New polynucleotides and polypeptides of the ifnalpha-21 gene |
| 07/19/2006 | EP1372640B1 Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of cns disorders |
| 07/19/2006 | EP1370556B1 Metalloproteinase inhibitors |
| 07/19/2006 | EP1301507B1 Mannich base prodrugs of 3 - (pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases |
| 07/19/2006 | EP1299361B1 Pyrazole derivatives |
| 07/19/2006 | EP1294721B1 Cyclic gmp-specific phosphodiesterase inhibitors |
| 07/19/2006 | EP1283725B1 Solid dispersion system of pranlukast with improved dissolution, and the preparing method thereof |
| 07/19/2006 | EP1282399B1 Rapidly disintegrating solid oral dosage form |
| 07/19/2006 | EP1268453B1 Estrogen agonist/antagonist metabolites |
| 07/19/2006 | EP1263740B1 Pyrimidine-4-one derivative as ldl-pla2 inhibitor |
| 07/19/2006 | EP1230920B1 Use of food materials in preventing and ameliorating metabolic bone diseases |
| 07/19/2006 | EP1223930B1 Treatment of dyskinesia |
| 07/19/2006 | EP1220684B1 Methods related to immunostimulatory nucleic acid-induced interferon |
| 07/19/2006 | EP1214129B1 Process for producing fine medicinal substances |
| 07/19/2006 | EP1194146B1 Arylthiazolidinedione and aryloxazolidinedione derivatives |
| 07/19/2006 | EP1181298B1 Novel 8a- and 9a-15-membered lactams |
| 07/19/2006 | EP1164991A4 Gels formed by the interaction of poly(aldehyde) with various substances |
| 07/19/2006 | EP1140107B1 Agonists and antagonists of peripheral-type benzodiazepine receptors |
| 07/19/2006 | EP1121109B8 Biphasic tramadol preparation |
| 07/19/2006 | EP1097927B1 Cyanoiminoquinoxaline derivatives |
| 07/19/2006 | EP1082337B1 17 beta-amino and hydroxylamino-11 beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 07/19/2006 | EP1077697B1 Methods and assays useful in the treatment of alcohol dependence or alcohol abuse |
| 07/19/2006 | EP1056452B1 Indole-3-propionic acids, salts and esters thereof used as medicaments |
| 07/19/2006 | EP0996447B1 Combination therapy for modulating the human sexual response |
| 07/19/2006 | EP0941083B1 Pharmaceutical compositions containing 3-iodo-1,2-propanediol having mucolytic activity |
| 07/19/2006 | EP0898580B1 Methods and means for inhibition of cdk4 activity |
| 07/19/2006 | EP0690724B1 Chlamydia vaccine comrising anti-idiotypic antibodies |
| 07/19/2006 | CN1805971A Method for obtaining a natural mixture of conjugated equine estrogens |
| 07/19/2006 | CN1805966A Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs |
| 07/19/2006 | CN1805965A Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
| 07/19/2006 | CN1805964A 1.3.4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives |
| 07/19/2006 | CN1805963A Cannabinoid receptor ligands and uses thereof |
| 07/19/2006 | CN1805960A 7-azaindoles and use thereof as therapeutic agents. |
| 07/19/2006 | CN1805959A Cycloalkanepyrrolopyridines as DP receptor antagonists |
| 07/19/2006 | CN1805957A Azetidine compounds |
| 07/19/2006 | CN1805956A Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| 07/19/2006 | CN1805954A Indole derivatives as serotonin reuptake inhibitors |
| 07/19/2006 | CN1805953A Indole derivatives as serotonin reuptake inhibitors |
| 07/19/2006 | CN1805952A Bicyclic indolyl derivatives and methods of their use as serotonergic agents |
| 07/19/2006 | CN1805948A Stabilized derivatives of ascorbic acid. |
| 07/19/2006 | CN1805944A Cyclic hydroxylamine as psychoactive compounds |
| 07/19/2006 | CN1805942A Diphenylurea derivatives and their use as chloride channel blockers |
| 07/19/2006 | CN1805940A Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| 07/19/2006 | CN1805939A Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases |
| 07/19/2006 | CN1805938A Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases |
| 07/19/2006 | CN1805937A N-[(piperazinyl)hetaryl]arylsulfonamide compounds with affinity for the dopamine D3 receptor. |
| 07/19/2006 | CN1805936A VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
| 07/19/2006 | CN1805935A Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic M3 receptor |
| 07/19/2006 | CN1805934A 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentlyoxybenzyl)piperidine as glucosylceramide synthase (GCS) inhibitor |
| 07/19/2006 | CN1805933A 2-hydroxymethyl-3,4,5-trihydroxy-1benzylpiperidine derivatives as inhibitors of glucosylceramide synthase (gcs) |
| 07/19/2006 | CN1805930A Hydroxamic acids useful in the treatment of hyper-proliferative disorders |
| 07/19/2006 | CN1805929A Phosphodiesterase 4 inhibitors |
| 07/19/2006 | CN1805927A 1- (alkylaminoalkyl-pyrolidin-/piperidinyl) -2, 2-diphenylacetamide derivatives as muscarinic receptor antagonists |
| 07/19/2006 | CN1805923A Benzamide derivative or salt thereof |
| 07/19/2006 | CN1805922A Pharmaceutically useful salts of carboxylic acid derivates |
| 07/19/2006 | CN1805769A CNS chloride modulation and uses thereof |
| 07/19/2006 | CN1805751A Methods of managing the symptoms of premenstrual syndrome. |
| 07/19/2006 | CN1805750A Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents |
| 07/19/2006 | CN1805749A New pharmaceutical uses of staurosporine derivatives |
| 07/19/2006 | CN1805748A 2-aminopyrimidine derivatives as RAF kinase inhibitors |
| 07/19/2006 | CN1805747A 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl-carbonyl)piperidine derivatives and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's |
| 07/19/2006 | CN1805746A Treatment for alzheimer's disease and related conditions |
| 07/19/2006 | CN1805745A 2-aminobenzothiazoles as CB1 receptor inverse agonists |
| 07/19/2006 | CN1805744A New n-hydroxy-4-(3-phenyl-5-methyl-isoxazole-4-yl)-benzenesulfonamide solvates |
| 07/19/2006 | CN1805743A RAGE antagonists as agents to reverse amyloidosis and diseases associated therewith |
| 07/19/2006 | CN1805742A Cis-imidazolines as MDM2 inhibitors |
| 07/19/2006 | CN1805741A Stable compositions of atorvastatin prepared with wet granulation |
| 07/19/2006 | CN1805740A Compositions for down-regulation of CCR5 expression and methods of use thereof |
| 07/19/2006 | CN1805739A Anti-inflammatory analgesic adhesive patch |
| 07/19/2006 | CN1805738A Extended-release tablets of metformin |
| 07/19/2006 | CN1805737A Memantine oral dosage forms |